当前位置: 首页 > 详情页

Remote limb ischemic conditioning treatment for intracranial atherosclerotic stenosis patients

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Center for Evidence Based Medicine, Xuanwu Hospital Capital Medical University, Beijing, China [2]Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing, China [3]Cerebrovascular Disease Laboratory, Xuanwu Hospital Capital Medical University, Beijing, China [4]Clinical Research Center, Peking University Health Science Center, Beijing, China [5]Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China [6]Department of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Intracranial atherosclerotic stenosis ischemia remote ischemic conditioning stroke

摘要:
Objective The recurrence rate of ischemic stroke remains high among symptomatic intracranial atherosclerotic stenosis patients with either ischemic stroke or transient ischemic attack. The aim of our study is to evaluate whether remote limb ischemic conditioning (RLIC) prevents cerebral ischemic events in symptomatic intracranial atherosclerotic stenosis patients. Methods Symptomatic intracranial atherosclerotic stenosis patients with either ischemic stroke or transient ischemic attack will be recruited from more than 60 hospitals in China to participate in a randomized, double-blind, parallel-controlled clinical trial that will compare the efficacy and safety of RLIC for the prevention of recurrent stroke. Following randomization, patients allocated to the RLIC group (n=1500) will receive RLIC once daily for 12 months, with treatment consisting of five cycles of 5min of pressure treatment at 200mm Hg, followed by 5min of reperfusion. The sham group (n=1500) will be treated identically, with the exception of pressure treatment at 60mm Hg. Results The primary endpoint will be an ischemic stroke event during the study period. Secondary endpoints will include composite fatal and nonfatal stroke, fatal and nonfatal myocardial infarction, and transient ischemic attack. Patients will be assessed periodically over a approximate 3-year study period using the modified Rankin Scale, National Institutes of Health Stroke Scale, and Barthel Activities of Daily Living Index. Conclusion We predict that RLIC treatment for 12 months will safely reduce the ischemic stroke recurrence rate.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 3 区 外周血管病
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学 2 区 外周血管病
JCR分区:
出版当年[2014]版:
Q1 PERIPHERAL VASCULAR DISEASE
最新[2023]版:
Q1 CLINICAL NEUROLOGY Q1 PERIPHERAL VASCULAR DISEASE

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Center for Evidence Based Medicine, Xuanwu Hospital Capital Medical University, Beijing, China
通讯作者:
通讯机构: [*1]Department of Neurosurgery, Xuanwu Hospital Capital Medical University, No. 45 Changchun Street, Beijing 100053, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院